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It is often useful for the physician to classify diabetes as stable
or unstable. Maturity-onset diabetes
is usually stable, and its management is not difficult, provided the
patient is interested and cooperative.
Tendency to obesity, relative insensitivity to insulin, and absence
of ketosis are characteristic of such
patients. Relative insensitivity to insulin does not imply unresponsiveness, but rather that the blood sugar
is not overly labile and does not
fall sharply in response to exercise
or injected insulin. Many patients
with such insensitivity to insulin are
adequately managed on diet, alone
or in combination with the oral hypoglycemic agents. When the latter
fail, usually a single morning dose
of long-acting insulin is satisfactory
in controlling glycosuria and hyperglycemia during a 24-hour interval. Occasionally a small dose of
crystalline insulin given in the same
injection will be needed to control
glycosuria between breakfast and
lunch.

UNSTABLE DIABETES

Unstable or "brittle" diabetes
usually is associated with the
growth-onset type, although it may
be present in many patients whose
diabetes appeared after the age of
40. "Brittle" diabetics are insulin
dependent and prone to ketosis.
They are usually of average or below average weight and often are
emotionally labile. Marked fluctuations in blood glucose following exercise or ingestion of food , as well
as during infections, may lead to
periods of marked hyperglycemia or
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hypoglycemia. These rapid and often unpredictable shifts in blood
glucose are disturbing to the patient and his family and frustrating
to the physician.
In considering the causes of unstable diabetes one must differentiate between primary instability
and transient conditions which may
influence diabetes unfavorably and
cause temporary instability. Stable
diabetes may be aggravated by a
number of conditions such as infection, thyrotoxicosis, and physical or
emotional stress. If treatment is
poorly planned or carried out, erratic behavior of the blood glucose
may result from giving excessively
large doses of insulin, or from giving it at the wrong time of day. Rebound hyperglycemia and occasionally ketosis may result from
excessive insulin administration and
may, in some instances, be responsible for periods of instability
in an otherwise stable diabetic
(Somogyi, 1960).
Primary instability characterizes
the "very brittle patient." The basic
cause is complete or nearly complete lack of endogenous insulin
production. This condition usually
manifests itself during the growth
years ; after diabetes has been present five years or more, little or no
insulin can be found in the blood.
Examination of pancreatic tissue
from a patient with this type of diabetes reveals little or no insulin.
This fact accounts for unresponsiveness to the sulfonylurea compounds wl1ose major action depends upon the ability of the
pancreas to1produce and release insulin.

The "brittle" diabetic is therefore totally dependent on exogenous
insulin. Normal homeostatic mechanisms concerned with the release
of pancreatic insulin in response to
metabolic needs are no longer present. The physician then faces a difficult task in attempting to supply
insulin by injection, in an effort to
prevent glycosuria and to maintain
the blood glucose at a normal level
throughout each 24-hour period.
As Dr. Alexander Marble paraphrased this problem, "One strives
to mimic nature, and, of course,
succeeds only imperfectly."
MANAGEMENT OF PRIMARY
INSTABILITY

In the management of the unstable or "brittle" diabetic, those
conditions which aggravate diabetes should be sought and treated.
One should carefully avoid overdosage of insulin. This is extremely
important since it is hypoglycemia,
not diabetes itself, that most often
incapacitates the diabetic in his
job and in many other social situations. Management is based on an
attempt to secure uniformity of the
controllable factors which influence
blood glucose. These include diet,
insulin, and physical activity. The
diet should be reasonably constant
from day to day in conjunction
with a relatively fixed , daily insulin
dose. Physical activity lowers the
requirement for injected insulin,
and strenuous or unusual exercise
may precipitate hypoglycemic episodes; in such circumstances additional food may be taken. If unusual physical activity is anticiMCV QUARTERLY 2(1): 28-31 , 1966
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pated, an appropriate decrease may
be made in the dose of insulin.
The "brittle" diabetic invariably
requires daily injections of insulin.
There are various insulin programs,
most of which include giving the
major portion of the day's insulin
in the form of a long-acting insulin,
either NPH or Lente insulin, as an
"anchor" dose before breakfast. If
one has been careful to keep uniform the patient's daily diet, exercise, and insulin dose, this single
morning dose may be all that is
needed to maintain blood glucose
within the normal range during a
24-hour period. Unfortunately, this
is most often not the case in the
unstable diabetic. Lack of uniformity, either in diet or exercise, while
receiving a relatively fixed dose of
daily insulin accounts for many of
the wide swings in blood glucose
following insulin injection.
In either stable or unstable diabetes, despite satisfactory control
in the afternoon and evening following a single morning dose of
long-acting insulin, the fasting
blood sugar may be high the following morning. One may effectively control this by a split dose
of long-acting insulin, employing a
smaller increment, usually 5 to 10
units, at bedtime. If the tests at
supper are poor, then giving this
smaller increment before supper
along with a small dose of regular
insulin may bring about satisfactory control. If either the single
morning dose or split dose brings
about satisfactory control before
breakfast and supper, yet fails to
control hyperglycemia and glycosuria before lunch, then a small
dose of crystalline insulin may be
given along with the pre-breakfast
injection of longer-acting insulin.
Adjustments in insulin dosage
are usually made in 3 to 5 unit
increments, allowing two to three
days between successive changes.
Ordinarily, changes in insulin dose
are not made frequently, and certainly not on the basis of a single
test, but rather according to the
general trend of tests at a given

time of day. The patient should
keep a record of urine tests so the
degree of control at any given time
of day can be easily ascertained.
Phenformin (DBI) has been
recommended as an additional supplement to insulin in "brittle" patients in an attempt to lessen fluctuations in the blood sugar. This
was tried without much success in
approximately 20 juvenile patients
over a two-year period at the MCV
diabetic clinic. The insulin dose was
significantly decreased, yet these
patients remained just as "brittle"
while on phenformin (DBI).

Causes of Primary Instability
Although the basic cause of primary instability seems to be nearly
total lack of endogenous insulin
production, the factors contributing
to the "brittle" state are poorly understood. The rebound phenomenon following excessive insulin dosage (Somogyi, 1960) all too often
is not corrected simply by reducing
insulin dosage. In many instances
this may result in an increasing frequency of periods of ketosis.
The capricious response of such
patients to insulin therapy might
arise from alterations in the handling and disposal of insulin in the
body. Prout and Katims (1959)
advanced the hypothesis that some
type of plasma binding of insulin
with erratic release of free insulin
might result in a variable clinical
response to the same dose of insulin. Lennon and others ( 1960)
have demonstrated in vivo that
such plasma binding is reflected in
prolonged plasma disappearance of
}181-labeled insulin. Although altered degradation of insulin by impaired renal or hepatic function
may play an important role, the
influence of previous insulin therapy appears to be a major factor
in this altered handling of exogenous insulin. This suggests that
binding of insulin by insulin-neutralizing antibodies may be an important cause.
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Differences in responsiveness of
muscle and adipose tissue to free
and complexed insulin may be important. Plasma-bound insulin may
be free to act on adipose tissue,
while only free insulin acts on muscle. Perhaps the insulin !ability
might result from the gradual saturation of plasma-binding sites with
complexed insulin free to act only
on adipose tissue. At a certain level
of dosage, saturation of the binding sites occurs, and free insulin is
then available to act on the mass
of muscle tissue, thus precipitating
hypoglycemia.
Bolinger ( 1964) demonstrated
markedly delayed disappearance
times of regular insulin in "brittle"
diabetics. The characteristics of
regular insulin in these subjects approached that of long-acting insulin.
He postulated that regulatory difficulties should be exaggerated by
the use of long-acting insulin, in
that the slow release rate of insulin
from injection sites approached the
rate of degradation, thus permitting
erratic ,filling of the plasma-binding
sites. He found that in general the
longer the disappearance time of
insulin, the greater the proportion
of regular insulin required for good
regulation.
INSULIN RESISTANCE

Another problem in insulinrequiring diabetics is the patient
whose insulin dose increases steadily. Insulin resistance has been arbitrarily defined as existing when the
daily insulin requirement exceeds
200 units. However, some degree
of resistance occurs in any individual requiring over 30 to 40 units
daily, since this amount provides
adequate replacement therapy in
depancreatized human subjects.
Many factors can increase the requirement for insulin in human diabetics and should be considered
whenever insulin dosage has to be
raised progressively. Insulin resistance resulting from any of these
. known factors is usually secondary
to such factors as obesity, keto~
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acidosis, infection, stress, puberty,
pregnancy, and a number of endocrine disturbances, notably thyrotoxicosis.
"Primary" or chronic insulin resistance is distinguished by the absence of any of the factors known
to aggravate diabetes. In most cases
it can be attributed to the development by the patient of y-globulin
antibodies to exogenous insulin and
primarily against the bovine insulin
component in most commercial
preparations which are usually mixtures of 70% bovine and 30%
pork insulin (Berson and Yalow,
1958; Berson et al., 1956; Field et
al., 1961).
In some cases of apparently primary resistance, anti-insulin antibodies cannot be demonstrated, and
high levels of active plasma insulin
seem to be physiologically ineffective (Field, 1960). Tissue unresponsiveness to insulin has been
postulated to explain such cases. It
is also theoretically possible that
primary insulin resistance could result from excessive amounts of
binding substances found in association with serum albumin or the
y- or fl-globulins.
Primary insulin resistance may
occur in either sex, at any age, and
in either stable or unstable diabetes
( Smelo, 1948). Some authors think
it occurs more commonly where insulin has been given intermittently
(Calvin and Moloney, 1959). The
onset is unpredictable and may terminate in a few weeks or persist
for several years ( Smelo, 1948) .
This fact makes evaluation of any
therapeutic program difficult. Susceptibility to keto-acidosis is about
the same as before the onset. Control of the diabetes is usually possible if enough insulin is given, and
prognosis is good for ultimate subsidence of the resistance (Smelo,
1948).
TREATMENT OF INSULIN

RESISTA~CE
I

The first important measure is to
give large enough doses of ordinary

commercial insulin. In most cases
there is a level which will ultimately overcome the resistance,
with subsequent improvement in
insulin sensitivity (Smelo, 1948).
Success may depend on willingness
to administer very large doses of
insulin, and on the realization that
subsequent increases in dosage must
be made by geometric progression.
With our knowledge of insulinneutralizing antibodies, a rational
treatment can be based on measures which influence antibody synthesis. Adrenal cortical steroids
have been used successfully (Field,
1962; Oakly et al., 1959), although the mechanism of their
beneficial effect is uncertain. Their
action may be mediated through an
effect either on inhibition of ant\body synthesis, or by influencing
the rate of dissociation of the
antigen-antibody complex.
Less antigenic types of insulin
other than commercial beef-pork
insulin have been used successfully.
Since the major antigenic property
of this mixture can be attributed to
beef insulin, whose molecular structure differs considerably from human insulin (Harris et al., 1956;
Berson and Yalow, 1959), pure
pork insulin has been used successfully in a number of cases (Goldman and Kaye, 1962; Feldman et
al., 1963). The molecular similarity of pork and human insulin
probably accounts for its weaker
antigenic properties (Harris et al.,
1956; Berson and Yalow, 1959) .
The human insulin molecule consists of two long amino acid chains
designated A and B chains joined
by disulfide bridges (Harris et al.,
1956) . Pork insulin differs only by
the terminal amino acid on the
long B chain. Other more antigenic
insulins such as beef insulin differ
by additional changes in the sequence of the important amino acid
triplet at the 8, 9, and 10 positions
enclosed within the disulfide bridge
on the shorter A chain.
Although not generally useful,
the sulfonylurea drugs have helped
in a few selected cases of mild insu-
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lin resistance. These patients have
usually been mild, maturity-onset
diabetics whose insulin doses have
had to be increased gradually over
a period of one to two years. Varying the insulin dose has usually
made little or no difference in the
ultimate control of their diabetes.
Since antibodies against commercial
insulin of animal origin do not significantly neutralize endogenous insulin, stimulation of pancreatic insulin by these agents may bring
about secretion of enough nonantigenic endogenous insulin to
control the diabetes.
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